Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Australian Genomics: Outcomes of a 5-year national program to accelerate the integration of genomics in healthcare.
Stark Z, Boughtwood T, Haas M, Braithwaite J, Gaff CL, Goranitis I, Spurdle AB, Hansen DP, Hofmann O, Laing N, Metcalfe S, Newson AJ, Scott HS, Thorne N, Ward RL, Dinger ME, Best S, Long JC, Grimmond SM, Pearson J, Waddell N, Barnett CP, Cook M, Field M, Fielding D, Fox SB, Gecz J, Jaffe A, Leventer RJ, Lockhart PJ, Lunke S, Mallett AJ, McGaughran J, Mileshkin L, Nones K, Roscioli T, Scheffer IE, Semsarian C, Simons C, Thomas DM, Thorburn DR, Tothill R, White D, Dunwoodie S, Simpson PT, Phillips P, Brion MJ, Finlay K, Quinn MC, Mattiske T, Tudini E, Boggs K, Murray S, Wells K, Cannings J, Sinclair AH, Christodoulou J, North KN. Stark Z, et al. Among authors: mileshkin l. Am J Hum Genet. 2023 Mar 2;110(3):419-426. doi: 10.1016/j.ajhg.2023.01.018. Am J Hum Genet. 2023. PMID: 36868206 Free PMC article. Review.
Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis.
Nagle CM, Olsen CM, Ibiebele TI, Spurdle AB, Webb PM; Astralian National Endometrial Cancer Study Group; Astralian Ovarian Cancer Study Group. Nagle CM, et al. Eur J Nutr. 2013 Mar;52(2):705-15. doi: 10.1007/s00394-012-0376-7. Epub 2012 May 22. Eur J Nutr. 2013. PMID: 22648201 Review.
Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA).
Smith D, Robledo KP, Yip S, Cummins MM, Kok PS, Lee YC, Friedlander M, Baron-Hay S, Shannon C, Coward J, Beale P, Goss G, Meniawy T, Lombard J, Spurdle AB, Andrews J, Stockler MR, Mileshkin L, Antill Y; Australia New Zealand Gynaecological Oncology Group (ANZGOG). Smith D, et al. Among authors: mileshkin l. Cancers (Basel). 2022 Dec 30;15(1):254. doi: 10.3390/cancers15010254. Cancers (Basel). 2022. PMID: 36612250 Free PMC article.
Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study.
Jordan S, Steer C, DeFazio A, Quinn M, Obermair A, Friedlander M, Francis J, O'Brien S, Goss G, Wyld D, Australian Ovarian Cancer Study Group, Webb P; Ovarian Cancer Patterns of Care Study Group. Jordan S, et al. Gynecol Oncol. 2013 May;129(2):310-7. doi: 10.1016/j.ygyno.2013.02.007. Epub 2013 Feb 9. Gynecol Oncol. 2013. PMID: 23403164 Free article.
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.
Friedlander M, Mileshkin L, Lombard J, Frentzas S, Gao B, Wilson M, Meniawy T, Baron-Hay S, Briscoe K, McCarthy N, Fountzilas C, Cervantes A, Ge R, Wu J, Spira A. Friedlander M, et al. Among authors: mileshkin l. Br J Cancer. 2023 Sep;129(5):797-810. doi: 10.1038/s41416-023-02349-0. Epub 2023 Jul 20. Br J Cancer. 2023. PMID: 37474720 Free PMC article. Clinical Trial.
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
Tjokrowidjaja A, Friedlander ML, Ledermann JA, Coleman RL, Mirza MR, Matulonis UA, Pujade-Lauraine E, Lord SJ, Scott CL, Goble S, York W, Lee CK; Gynecologic Cancer Intergroup Meta-Analysis Committee. Tjokrowidjaja A, et al. J Clin Oncol. 2024 Apr 10;42(11):1301-1310. doi: 10.1200/JCO.23.01182. Epub 2024 Jan 12. J Clin Oncol. 2024. PMID: 38215359
Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial.
Werner B, Sjoquist KM, Espinoza D, Yip S, Chang G, Cummins MM, Mileshkin L, Ananda S, Shannon C, Friedlander M, Warton K, Ford CE. Werner B, et al. Among authors: mileshkin l. Transl Oncol. 2024 May;43:101914. doi: 10.1016/j.tranon.2024.101914. Epub 2024 Feb 27. Transl Oncol. 2024. PMID: 38417292 Free PMC article.
Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation.
Kaya M, Post CCB, Tops CM, Nielsen M, Crosbie EJ, Leary A, Mileshkin LR, Han K, Bessette P, de Boer SM, Jürgenliemk-Schulz IM, Lutgens L, Jobsen JJ, Haverkort MAD, Nout RA, Kroep J, Creutzberg CL, Smit VTHBM, Horeweg N, van Wezel T, Bosse T. Kaya M, et al. Among authors: mileshkin lr. Mod Pathol. 2024 Mar;37(3):100423. doi: 10.1016/j.modpat.2024.100423. Epub 2024 Jan 6. Mod Pathol. 2024. PMID: 38191122 Free article.
279 results